Roche has received CE Mark for Elecsys pTau217, a blood test for Alzheimer's disease pathology developed in collaboration with Eli Lilly. This test uses a single-assay design to measure the pTau217 protein, an indicator of amyloid pathology. The test aims to aid in earlier and more accessible Alzheimer's disease diagnosis. It offers a more convenient and less invasive alternative to current methods. The test's accuracy is comparable to spinal fluid diagnostics and PET-CT scans. A positive result indicates a high likelihood of amyloid pathology, guiding clinicians. A negative result suggests a low likelihood, potentially ruling out Alzheimer's. The test is designed for use in primary and secondary care. The launch marks a significant step towards earlier diagnosis and timely intervention.